Leverone Jason A.

SEC source: 0001692747-26-000005 · form4-09232026_080937.xml · nonDerivative · entry 1

Leverone Jason A. · CIK 0001692747 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,500

F1 · kind: These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $2.95 to $3.06. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

SEC source: 0001692747-26-000004 · form4-08112026_080837.xml · derivative · entry 7

Leverone Jason A. · CIK 0001692747 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,611

Underlying: Class A Common Stock · 130,611 shares

Expires 2034-10-03

F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date.

F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options.

F6 · derivative.exercise_date: 1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

SEC source: 0001692747-26-000004 · form4-08112026_080837.xml · derivative · entry 6

Leverone Jason A. · CIK 0001692747 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 130,611 shares

Expires 2034-10-03

F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date.

F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options.

F6 · derivative.exercise_date: 1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

SEC source: 0001692747-26-000004 · form4-08112026_080837.xml · derivative · entry 5

Leverone Jason A. · CIK 0001692747 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,322

Underlying: Class A Common Stock · 5,322 shares

Expires 2033-08-29

F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date.

F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options.

F5 · derivative.exercise_date: 1/48th of the shares subject to the option vested on May 1, 2023 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

SEC source: 0001692747-26-000004 · form4-08112026_080837.xml · derivative · entry 4

Leverone Jason A. · CIK 0001692747 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 5,322 shares

Expires 2033-08-29

F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date.

F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options.

F5 · derivative.exercise_date: 1/48th of the shares subject to the option vested on May 1, 2023 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

SEC source: 0001692747-26-000004 · form4-08112026_080837.xml · derivative · entry 3

Leverone Jason A. · CIK 0001692747 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,781

Underlying: Class A Common Stock · 5,781 shares

Expires 2032-01-10

F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date.

F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options.

F2 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof.

SEC source: 0001692747-26-000004 · form4-08112026_080837.xml · derivative · entry 2

Leverone Jason A. · CIK 0001692747 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 5,781 shares

Expires 2032-01-10

F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date.

F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options.

F2 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof.

SEC source: 0001692747-26-000004 · form4-08112026_080837.xml · derivative · entry 1

Leverone Jason A. · CIK 0001692747 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Class A Common Stock · 50,000 shares

Expires 2036-08-06

F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on September 7, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

SEC source: 0001692747-26-000003 · form4-06242026_110637.xml · nonDerivative · entry 1

Leverone Jason A. · CIK 0001692747 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,802

F1 · kind: These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $4.27 to $4.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

F4 · balance_after: Includes 3,105 shares acquired under the Issuer's 2024 Employee Stock Purchase Plan on May 20, 2026.

SEC source: 0001692747-26-000002 · form4-04032026_070438.xml · derivative · entry 1

Leverone Jason A. · CIK 0001692747 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,000

Underlying: Class A Common Stock · 110,000 shares

Expires 2036-03-31

F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on May 1, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

SEC source: 0001692747-26-000001 · form4-03242026_100303.xml · nonDerivative · entry 1

Leverone Jason A. · CIK 0001692747 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

F1 · kind: These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $3.995 to $4.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

SEC source: 0001692747-25-000004 · form4-12242025_011233.xml · nonDerivative · entry 1

Leverone Jason A. · CIK 0001692747 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,301

F1 · kind: These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $2.82 to $3.04. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

F4 · balance_after: Includes 4,000 shares acquired under the Issuer's 2024 Employee Stock Purchase Plan on November 20, 2025.

SEC source: 0001692747-25-000003 · form4-09242025_110914.xml · nonDerivative · entry 1

Leverone Jason A. · CIK 0001692747 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,603

F1 · kind: These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $2.60 to $2.645. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

SEC source: 0001415889-25-018234 · form4-06252025_100636.xml · nonDerivative · entry 1

Leverone Jason A. · CIK 0001692747 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,906

F1 · kind: These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $2.33 to $2.47. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

SEC source: 0001415889-25-010418 · form4-04082025_090445.xml · nonDerivative · entry 2

Leverone Jason A. · CIK 0001692747 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,209

F1 · kind: These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.

F4 · price: This transaction was executed in multiple trades at prices ranging from $2.57 to $3.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

SEC source: 0001415889-25-010418 · form4-04082025_090445.xml · nonDerivative · entry 1

Leverone Jason A. · CIK 0001692747 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,053

F1 · kind: These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $3.10 to $3.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

SEC source: 0001415889-25-002311 · form4-01302025_010107.xml · derivative · entry 1

Leverone Jason A. · CIK 0001692747 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Class A Common Stock · 65,000 shares

Expires 2035-01-26

F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on February 27, 2025 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

SEC source: 0001415889-24-024918 · form4-10082024_111036.xml · derivative · entry 4

Leverone Jason A. · CIK 0001692747 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,611

Underlying: Class A Common Stock · 130,611 shares

Expires 2034-10-03

F6 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest on November 4, 2024 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

SEC source: 0001415889-24-024918 · form4-10082024_111036.xml · derivative · entry 3

Leverone Jason A. · CIK 0001692747 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,322

Underlying: Class A Common Stock · 5,322 shares

Expires 2033-08-29

F4 · price: Each OnKure stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Reneo and became an option to acquire, on the same terms and conditions as were applicable to such OnKure stock option immediately prior to the effective time of the Merger, a number of shares of Reneo Class A common stock equal to the number of shares of OnKure common stock subject to the unexercised portion of the OnKure stock option immediately prior to the effective time of the Merger, multiplied by a designated exchange ratio (rounded down to the nearest whole share). The exercise price per share for the options is equal to the exercise price per share of such OnKure stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent).

F5 · derivative.exercise_date: 1/48th of the shares subject to the option vested on May 1, 2023 and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person continuing as a service provider through each such date.

SEC source: 0001415889-24-024918 · form4-10082024_111036.xml · derivative · entry 2

Leverone Jason A. · CIK 0001692747 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,781

Underlying: Class A Common Stock · 5,781 shares

Expires 2032-01-10

F4 · price: Each OnKure stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Reneo and became an option to acquire, on the same terms and conditions as were applicable to such OnKure stock option immediately prior to the effective time of the Merger, a number of shares of Reneo Class A common stock equal to the number of shares of OnKure common stock subject to the unexercised portion of the OnKure stock option immediately prior to the effective time of the Merger, multiplied by a designated exchange ratio (rounded down to the nearest whole share). The exercise price per share for the options is equal to the exercise price per share of such OnKure stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent).

F3 · derivative.exercise_date: 1/4th of the shares subject to the option vested on January 3, 2023 and 1/48th of the shares subject to the option vest on the first day of each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

SEC source: 0001415889-24-024918 · form4-10082024_111036.xml · nonDerivative · entry 1

Leverone Jason A. · CIK 0001692747 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,331

F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon the meeting of both a "Service-Based Requirement" and a "Liquidity Event Plus Service Requirement." 1/16th of the RSUs met the "Service-Based" requirement on June 20, 2023 and 1/16th of the RSUs are scheduled to meet the Service-Based Requirement on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. The Liquidity Event Plus Service Requirement will be satisfied on the 181st day following the closing of the Merger (as defined below), subject to the Reporting Person continuing as a service provider through such date. On October 4, 2024, the effective time of the Merger, each RSU of OnKure (as defined below) (footnote continued in footnote (2))

F2 · shares: (continued from footnote (1)) was assumed by, and converted into an RSU award of, Reneo (as defined below) covering such number of shares of Reneo Class A Common Stock determined by multiplying the number of shares of OnKure preferred stock subject to the RSU award by a designated exchange ratio (rounded down to the nearest whole share). The Agreement and Plan of Merger, dated as of May 10, 2024 (the "Merger Agreement"), by and among Reneo Pharmaceuticals, Inc. ("Reneo"), Radiate Merger Sub I, a wholly owned subsidiary of Reneo ("Merger Sub I"), and OnKure, Inc. ("OnKure"), provided for the merger of Merger Sub I with and into OnKure, with OnKure surviving the merger as a wholly-owned subsidiary of Reneo (the "Merger"). After completion of the Merger, the combined company was renamed "OnKure Therapeutics, Inc." and the Class A Common Stock of the combined company trades on The Nasdaq Stock Market under the symbol "OKUR."

F1 · price: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon the meeting of both a "Service-Based Requirement" and a "Liquidity Event Plus Service Requirement." 1/16th of the RSUs met the "Service-Based" requirement on June 20, 2023 and 1/16th of the RSUs are scheduled to meet the Service-Based Requirement on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. The Liquidity Event Plus Service Requirement will be satisfied on the 181st day following the closing of the Merger (as defined below), subject to the Reporting Person continuing as a service provider through such date. On October 4, 2024, the effective time of the Merger, each RSU of OnKure (as defined below) (footnote continued in footnote (2))

F2 · price: (continued from footnote (1)) was assumed by, and converted into an RSU award of, Reneo (as defined below) covering such number of shares of Reneo Class A Common Stock determined by multiplying the number of shares of OnKure preferred stock subject to the RSU award by a designated exchange ratio (rounded down to the nearest whole share). The Agreement and Plan of Merger, dated as of May 10, 2024 (the "Merger Agreement"), by and among Reneo Pharmaceuticals, Inc. ("Reneo"), Radiate Merger Sub I, a wholly owned subsidiary of Reneo ("Merger Sub I"), and OnKure, Inc. ("OnKure"), provided for the merger of Merger Sub I with and into OnKure, with OnKure surviving the merger as a wholly-owned subsidiary of Reneo (the "Merger"). After completion of the Merger, the combined company was renamed "OnKure Therapeutics, Inc." and the Class A Common Stock of the combined company trades on The Nasdaq Stock Market under the symbol "OKUR."

SEC source: 0000899243-21-002488 · doc4.xml · derivative · entry 1

Leverone Jason A. · CIK 0001692747 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 311,785

Underlying: Common Stock · 311,785 shares

Expires 2031-01-17

F1 · derivative.exercise_date: The option vests in equal monthly installments over the following 4 years, subject to the Reporting Person's continued service to Issuer through each vesting date.

SEC source: 0001209191-20-019580 · doc4.xml · derivative · entry 2

Leverone Jason A. · CIK 0001692747 · CFO, Treasurer & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,249 shares

Expires 2020-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option is fully vested and exercisable. The option expires ten years after the date of grant.

SEC source: 0001209191-20-019580 · doc4.xml · nonDerivative · entry 1

Leverone Jason A. · CIK 0001692747 · CFO, Treasurer & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,829

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 1,250 shares acquired under the Miragen Therapeutics, Inc. 2015 Employee Stock Purchase Plan on February 21, 2020.

SEC source: 0001209191-20-009786 · doc4.xml · derivative · entry 1

Leverone Jason A. · CIK 0001692747 · CFO, Treasurer & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 185,000

Underlying: Common Stock · 185,000 shares

Expires 2030-02-11

F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan"). The shares shall vest as follows: (i) 50% shall vest in 48 equal monthly installments beginning on March 12, 2020, (ii) 25% shall vest on completion of a specified milestone related to cobomarsen development and (iii) 25% shall vest on completion of a specified milestone related to MRG-229 development, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in and as determined under the Plan. The shares underlying the option are subject to accelerated vesting upon the occurrence of specified events including a change of control of the Issuer and the Reporting Person's termination. The option expires ten years after the date of grant.

SEC source: 0001209191-19-047367 · doc4.xml · derivative · entry 2

Leverone Jason A. · CIK 0001692747 · CFO, Treasurer & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,093 shares

Expires 2019-09-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option is fully vested and exercisable. The option expires ten years after the date of grant.

SEC source: 0001209191-19-047367 · doc4.xml · nonDerivative · entry 1

Leverone Jason A. · CIK 0001692747 · CFO, Treasurer & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,330

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 1,250 shares acquired under the Miragen Therapeutics, Inc. 2015 Employee Stock Purchase Plan on February 22, 2019.

SEC source: 0001209191-19-008530 · doc4.xml · derivative · entry 1

Leverone Jason A. · CIK 0001692747 · CFO, Treasurer & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2029-02-05

F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan"). 6.25% of the shares will vest on May 7, 2019 and the remaining 93.75% of the shares will vest in equal monthly installments thereafter over 45 months, such that the stock option shall be fully vested on the four-year anniversary of the date of grant, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in and as determined under the Plan. The shares underlying the option are subject to accelerated vesting upon the occurrence of specified events including a change of control of the Issuer and the Reporting Person's termination. The option expires ten years after the date of grant.

SEC source: 0001209191-18-046026 · doc4.xml · derivative · entry 2

Leverone Jason A. · CIK 0001692747 · CFO, Treasurer & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 29,530 shares

Expires 2018-12-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option is fully vested and exercisable. The option expires ten years after the date of grant.

SEC source: 0001209191-18-046026 · doc4.xml · nonDerivative · entry 1

Leverone Jason A. · CIK 0001692747 · CFO, Treasurer & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,737

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-18-007269 · doc4.xml · derivative · entry 1

Leverone Jason A. · CIK 0001692747 · CFO, Treasurer & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2028-01-30

F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan"). 6.25% of the shares will vest on April 30, 2018 and the remaining 93.75% of the shares will vest in equal monthly installments thereafter over 45 months, such that the stock option shall be fully vested on the four-year anniversary of the date of grant, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in and as determined under the Plan. The shares underlying the option are subject to accelerated vesting upon the occurrence of specified events including a change of control of the Issuer and the Reporting Person's termination. The option expires ten years after the date of grant.

SEC source: 0001209191-17-011783 · doc4.xml · derivative · entry 1

Leverone Jason A. · CIK 0001692747 · CFO, Treasurer & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,500

Underlying: Common Stock · 77,500 shares

Expires 2027-02-15

F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan"). The shares vest in 48 equal monthly installments beginning on February 16, 2017, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in and as determined under the Plan. The shares underlying the option are subject to accelerated vesting upon the occurrence of specified events including a change of control of the Issuer and the Reporting Person's termination. The option expires ten years after the date of grant.